ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: PP05

Coping Through Advocacy – My Story Living with Relapsing Polychondritis

Allegonda Imeson1, 1The Canadian Society for Relapsing Polychondritis, Stony Plain, AB, Canada

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, cartilage, Cartilage Degradation, Inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Patient Perspectives Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Becoming a mother was the most pivotal moment of my life. From early on, I instilled the importance of a physical, healthy lifestyle for my two boys. I encouraged adventure and exploration with biking, walking and swimming in our picturesque Canadian backdrop.

In 2011, I started to experience painful swelling of the cartilaginous portions of my ears – which was so intense, I could not function. I was treated consistently and unsuccessfully with antibiotics. I was weak, tired, and in a constant state of cloudiness – I could no longer keep up with my children. As time moved forward, the episodes increased in intensity and frequency, and I started experiencing debilitating joint pain. Everyday was a struggle.

After finally being referred to a rheumatologist in 2015,  I was diagnosed with the rare and sometimes fatal disease Relapsing Polychondritis (RP). Although relieved to finally have an answer, I was distraught with the lack of resources and information available for RP.

Intervention:

The complexities of RP require a multidisciplinary team. Although treatment was started swiftly, the doctors I met with admittedly knew little of the disease. I decided to do whatever I could to educate myself about the illness. In late 2015, I reached out to the Relapsing Polychondritis Foundation and became the first international advocate for the U.S based group – eventually meeting a fellow patient in person at the 2016 LA autoimmune walk.

After this inspiring encounter, I decided to expand my international mission of awareness for RP. In 2017, I spearheaded the creation of the Canadian Society for Relapsing Polychondritis (CSRP) and successfully established the first Canadian RP non-profit organization focused on awareness, education, and patient support.

Maintenance:

As Chair of the CSRP, I lead in the organization of annual awareness campaigns in Canada. Our inaugural event featured medical professionals speaking about the illness to a crowd of 100, which was only a dream a few years previous. Each subsequent CSRP event has seen an increase in attendees – promoting awareness and encouraging patient wellness while focusing on what those with RP CAN do.

I proudly represent the CSRP in partnerships with the RP Foundation and Race for RP, attending the past three American College of Rheumatology (ACR) conferences alongside these organizations. I have had the honor of meeting experts in the field of rheumatology and the privilege of attending the 2019 RP investigators meeting – an international collaboration of professionals and advocates interested in the advancement of research for RP.

Quality of Life:

RP will forever be synonymous with who I am. Although I am plagued with the effects of the disease everyday, I am grateful for my ability to increase awareness.

Supporting those who feel like I did 5 years ago when I was first diagnosed has been the most rewarding aspect for me living with a rare autoimmune disease. I have solace in knowing that that my efforts, and the efforts of our international team, are helping others with RP.

Although it is difficult to be exactly who I was before RP, I am now instilling the power of knowledge and advocacy in my children. Teaching them that when life throws you obstacles, it is important to face them head on as there is strength in knowledge.

Allegonda Imeson and the Canadian Society for Relapsing Polychondritis (CSRP).

Allegonda Imeson and her family.

The Canadian Society for Relapsing Polychondritis (CSRP) logo.


Disclosure: A. Imeson, None.

To cite this abstract in AMA style:

Imeson A. Coping Through Advocacy – My Story Living with Relapsing Polychondritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/coping-through-advocacy-my-story-living-with-relapsing-polychondritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/coping-through-advocacy-my-story-living-with-relapsing-polychondritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology